Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Hyangsayukgunja-tang (MHYT) is a multi-component herbal medicine derived from traditional Korean medicine, specifically adapted from the classic Hyangsayukgunja-tang formula to treat gastrointestinal motility disorders and cancer-related symptoms. The formulation typically consists of a complex mixture of medicinal herbs, including *Panax ginseng*, *Atractylodes macrocephala*, *Poria cocos*, *Glycyrrhiza uralensis*, *Citrus reticulata*, and *Pinellia ternata*, often supplemented with additional herbs like *Crataegus pinnatifida* to enhance its prokinetic effects. MHYT exerts its therapeutic action by modulating the ghrelin system, specifically increasing levels of acylated ghrelin to stimulate appetite, and by interacting with serotonin receptors (5-HT3 and 5-HT4) to improve gastric accommodation and emptying. It is primarily investigated for the treatment of functional dyspepsia and cancer-related anorexia-cachexia syndrome (CACS), aiming to alleviate symptoms such as early satiety, postprandial bloating, and weight loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified hyangsayukgunja-tang.